SGLT2 Inhibitors: A Game-Changer in Cardiovascular Health and High-Risk Patient Care

A recent meta-analysis confirms the consistent benefits of SGLT2 inhibitors in reducing the risks of cardiovascular death and heart failure hospitalization in patients with HF, type 2 diabetes, and CKD.